Is It Time to Introduce PET/CT in Colon Cancer Guidelines?
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
pubmed:
21
5
2020
medline:
9
10
2020
entrez:
21
5
2020
Statut:
ppublish
Résumé
International colon cancer guidelines suggest F-FDG PET/CT in a few circumstances: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma; (2) in the workup of recurrent colon cancer with metachronous metastases documented by CT, MRI, or biopsy and in case of serial CEA elevation with negative colonoscopy and negative CT; and (3) in case of contraindication to iodine- and gadolinium-based contrast agents. However, review of the literature has shown that PET/CT can also be used in other scenarios with significant levels of diagnostic advantage. This review aims to emphasize differences between guidelines and scientific literature for the use of PET/CT in colon cancer.
Identifiants
pubmed: 32433179
doi: 10.1097/RLU.0000000000003076
pii: 00003072-202007000-00005
doi:
Substances chimiques
Contrast Media
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-530Références
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–2516.
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642.
Treglia G, Taralli S, Salsano M, et al. Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol. 2014;48:99–104.
Minamimoto R, Senda M, Jinnouchi S, et al. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a Nationwide Japanese survey. Ann Nucl Med. 2014;28:212–219.
Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med. 2004;45:1804–1810.
Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–762.
Even-Sapir E, Lerman H, Gutman M, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging. 2006;33:541–552.
Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol. 2005;185:495–500.
Lee JC, Hartnett GF, Hughes BG, et al. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun. 2009;30:333–337.
Fuertes J, Montagut C, Bullich S, et al. Incidental focal uptake in colorectal location on oncologic 18FDG PET and PET/CT studies: histopathological findings and clinical significances. Rev Esp Med Nucl Imagen Mol. 2015;34:95–101.
Servente L, Gigirey V, Fontes MG, et al. Incidental focal colonic uptake in studies 18F-FDG PET/CT. Rev Esp Med Nucl Imagen Mol. 2018;37:15–19.
Cho SH, Kim SW, Kim WC, et al. Incidental focal colorectal 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography. World J Gastroenterol. 2013;19:3453–3458.
Løberg M, Kalager M, Holme Ø, et al. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med. 2014;371:799–807.
Culverwell AD, Chowdhury FU, Scarsbrook AF. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal Cancer. Abdom Imaging. 2012;37:1021–1031.
Yasuda S, Takahashi W, Takagi S, et al. Factors influencing physiological FDG uptake in the intestine. Tokai J Exp Clin Med. 1998;23:241–244.
Massollo M, Marini C, Frignone M, et al. Metformin temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice. J Nucl Med. 2013;54:259–266.
Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95–99.
Bahler L, Holleman F, Chan MW, et al. 18F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure. PLoS One. 2017;12:e0176242.
Ozülker T, Ozülker F, Mert M, et al. Clearance of the high intestinal (18)F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging. 2010;37:1011–1017.
Lee SH, Jin S, Lee HS. Metformin discontinuation less than 72 H is suboptimal for F-18 FDG PET/CT interpretation of the bowel. Ann Nucl Med. 2016;30:629–636.
Minamimoto R, Terauchi T, Jinnouchi S, et al. Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake. Ann Nucl Med. 2013;27:468–477.
Toriihara A, Yoshida K, Umehara I, et al. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging. Ann Nucl Med. 2011;25:173–178.
Miyake KK, Nakamoto Y, Togashi K. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning. Ann Nucl Med. 2012;26:492–500.
Chen YK, Chen JH, Tsui CC, et al. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET. Radiology. 2011;259:525–533.
Nerad E, Lahaye MJ, Maas M, et al. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. Am J Roentgenol. 2016;207:984–995.
Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674–684.
Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014;101:613–621.
Laurens ST, Oyen WJ. Impact of fluorodeoxyglucose PET/computed tomography on the management of patients with colorectal cancer. PET Clin. 2015;10:345–360.
Ye Y, Liu T, Lu L, et al. Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients. Int J Clin Exp Med. 2015;8:21773–21785.
Huang J, Huang L, Zhou J, et al. Elevated tumor-to-liver uptake ratio (TLR) from 18F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:1958–1968.
Veit-Haibach P, Kuehle CA, Beyer T, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA. 2006;296:2590–2600.
Lee JY, Ock M, Jo MW, et al. Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea. Sci Rep. 2017;7:5571.
Sasaki K, Kawasaki H, Sato M, et al. Impact of Fluorine-18 2-Fluoro-2-deoxy-D-glucose uptake on preoperative positron emission tomography/computed tomography in the lymph nodes of patients with primary colorectal cancer. Dig Surg. 2017;34:60–67.
Lee JH, Lee MR. Positron emission tomography/computed tomography in the staging of Colon Cancer. Ann Coloproctol. 2014;30:23–27.
Kawashima K, Kato K, Tomabechi M, et al. Clinical evaluation of (18)F-fludeoxyglucose positron emission tomography/CT using point spread function reconstruction for nodal staging of colorectal cancer. Br J Radiol. 2016;89:20150938.
Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036–1041.
Grut H, Dueland S, Line PD, et al. The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2018;45:218–225.
Shim JR, Lee SD, Han SS, et al. Prognostic significance of 18F-FDG PET/CT in patients with colorectal cancer liver metastases after hepatectomy. Eur J Surg Oncol. 2018;44:670–676.
Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014;311:1863–1869.
Maffione AM, Lopci E, Bluemel C, et al. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015;42:152–163.
McLeish AR, Lee ST, Byrne AJ, et al. Impact of 18F-FDG-PET in decision making for liver metastectomy of colorectal cancer. ANZ J Surg. 2012;82:30–35.
Oh JW, Oh SN, Choi JI, et al. Does the gadoxetic acid-enhanced liver MRI impact on the treatment of patients with colorectal cancer? Comparison study with 18F-FDG PET/CT. Biomed Res Int. 2016;2016:8412071.
Schulz A, Viktil E, Godt JC, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57:1040–1048.
Dirisamer A, Halpern BS, Flöry D, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol. 2010;73:324–328.
Morbelli S, Conzi R, Campus C, et al. Contrast-enhanced [18F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography. Cancer Imaging. 2014;14:10.
Revheim ME, Haugvik SP, Johnsrud K, et al. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases. Acta Radiol. 2015;56:397–403.
Annunziata S, Caldarella C, Treglia G. Cost-effectiveness of fluorine-18-fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: a systematic review. World J Radiol. 2014;6:48–55.
Khan K, Athauda A, Aitken K, et al. Survival outcomes in asymptomatic patients with normal conventional imaging but raised carcinoembryonic antigen levels in colorectal cancer following positron emission tomography-computed tomography imaging. Oncologist. 2016;21:1502–1508.
Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, et al. Intensive follow-up strategies improve outcomes in non-metastatic colorectal cancer patients after curative surgery. A systematic review and meta-analysis. Ann Oncol. 2015;26:644–656.
NCCN Clinical Practice Guidelines in Oncology Colon Cancer Version 4. 2018. Available at: www.nccn.org.
Sargent D, Sombrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–877.
Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108:9–13.
Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263–270.
Rosati G, Ambrosini G, Barni S, et al. A randomized trial of intensive versus minimal surveillance of patients with resected dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274–280.
Shinkins B, Nicholson BD, James T, et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol Assess. 2017;21:1–60.
Litvak A, Cercek A, Segal N, et al. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw. 2014;12:907–913.
Sobhani I, Itti E, Luciani A, et al. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised. Trial Ann Oncol. 2018;29:931–937.
Marcus C, Marashdeh W, Ahn SJ, et al. 18F-FDG PET/CT and colorectal cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. J Nucl Med. 2015;56:989–994.
Pema PJ, Bennett WF, Bova JG, et al. CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma. J Comput Assist Tomogr. 1994;18:256–261.
Vreugdenburg TD, Ma N, Duncan JK, et al. Comparative diagnostic accuracy of hepatocyte specific gadoxetic acid (Gd-EOB-DTPA) improved MRI imaging and improved contrast CT for detection of liver metastases: a systematic review and a meta-analysis. Int J Colorectal Dis. 2016;31:1739–1749.
Mittal BR, Senthil R, Kashyap R, et al. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun. 2011;32:789–793.
Huang YY, Lee PI, Liu MC, et al. A general cutoff level combined with personalized dynamic change of serum carcinoembryonic antigen can suggest timely use of FDG PET for early detection of recurrent colorectal cancer. Clin Nucl Med. 2015;40:e465–e469.
Caglar M, Yener C, Karabulut E. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer. Int J Comput Assist Radiol Surg. 2015;10:993–1002.
Sanli Y, Kuyumcu S, Ozkan ZG, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012;26:551–558.
Yu T, Meng N, Chi D, et al. Diagnostic value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. 2015;72:443–451.
Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1451–1457.
Ince S, Okuyucu K, Hancerliogulları O, et al. Clinical significance of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in the follow-up of colorectal cancer: searching off approaches increasing specificity for detection of recurrence. Radiol Oncol. 2017;51:378–385.
Marcus C, Wray R, Taghipour M, et al. Journal club: value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival. AJR Am J Roentgenol. 2016;207:257–265.
Soyka JD, Veit-Haibach P, Strobel K, et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice? J Nucl Med. 2008;49:354–361.
Sarikaya I, Povoski SP, Al-Saif OH, et al. Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer. World J Surg Oncol. 2007;5:80.
Salvatore L, Aprile G, Arnoldi E, et al. Metastatic colorectal management cancer patients: Italian guidelines Medical Oncology Association (AIOM). ESMO Open. 2017;2:e000147.
Habr-Gama A, Gama-Rodrigues J, Perez RO. Is the tailored treatment of rectal cancer the only real advantage of long-term neoadjuvant chemoradiotherapy? Dis Colon Rectum. 2013;56:264–266.
Quah HM, Chou JF, Gonen M, et al. The pathological stage is more prognostic than after disease-free survival in patients with locally advanced rectal cancer preoperative chemoradiotherapy. Cancer. 2008;113:57–64.
Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of calculated morphological criteria of tomography with pathological response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–2344.
Walker AS, Zwintscher NP, Johnson EK, et al. Future directions for monitoring treatment response in colorectal cancer. J Cancer. 2014;5:44–57.
Ricotta R, Vanzulli A, Moroni M, et al. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. Clin Colorectal Cancer. 2013;12:45–5337.
Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011;18:2224–2231.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.
Xia Q, Liu J, Wu C, et al. Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging. 2015;15:19.
Jadvar H, Colletti PM, Delgado-Bolton R, et al. Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58:2026–2037.
Poulou LS, Ziakas PD, Ziogas DC, et al. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. Biomarkers. 2012;17:532–538.
Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713–8716.
Berger AK, Lücke S, Abel U, et al. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. Br J Cancer. 2018;119:170–175.
Liu FY, Yen TC, Wang JY, et al. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy. Clin Nucl Med. 2015;40:200–205.
Skougaard K, Johannesen HH, Nielsen D, et al. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Med. 2014;3:1294–1301.
Woff E, Hendlisz A, Garcia C, et al. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 2016;43:1792–1801.
Kawada K, Toda K, Nakamoto Y, et al. Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med. 2015;56:1322–1327.